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We have recently reported that vatalanib, an orally active small
molecule multi-tyrosine kinase inhibitor (Hess-Stumpp et al., 2005
[1]), can sensitize multidrug resistant (MDR) colon cancer cells to
chemotherapy under hypoxia by inhibiting two MDR transporters
ABCB1 and ABCG2 (To et al., 2015 [2]). This data article describes
the possible circumvention of resistance to speciﬁcally platinum
(Pt)-based anticancer drugs by vatalanib via inhibition of two other
efﬂux transporters ABCC2 and ATP7A. Data from the ﬂow cyto-
metric transporter efﬂux assay showed speciﬁc inhibition of ABCC2
activity by vatalanib in stable transfected cells and ABCC2-
overexpressing oxaliplatin-resistant colon cancer cells HCT116/
Oxa. We also performed the transporter ABCC2 ATPase assay and
showed an increase in ATP hydrolysis by ABCC2 in the presence of
vatalanib. ATP7A mRNA expression was also shown to be upre-
gulated in HCT116/Oxa cells. Vatalanib was shown to suppress this
upregulated ATP7A expression. Data from the cellular Pt accumu-
lation assay showed a lower Pt accumulation in HCT116/Oxa cells
than the parental sensitive HCT116 cells. Vatalanib was shown to
increase cellular Pt accumulation in a concentration-dependent
manner. Combination of oxaliplatin and vatalanib was shown to
restore the suppressed apoptosis in HCT116/Oxa cells.
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
.W. To), fulw@mail.sysu.edu.cn (L.-w. Fu).
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 Data show the circumvention of platinum resistance by combination of oxaliplatin and vatalanib in
an oxaliplatin-resistant human colon cancer cell line HCT116/Oxa.
 Data show the upregulation of two efﬂux transporters (multidrug resistance-associated protein 2
(ABCC2) and copper efﬂux transporter (ATP7A)) in oxaliplatin-resistant colon cancer cells (HCT116/
Oxa).
 Data show the inhibition of ABCC2 transporter activity by vatalanib.
 Data demonstrate the downregulation of ATP7A expression by vatalanib.
 The data may be valuable for future studies investigating the beneﬁcial cytotoxic effect by com-
bining vatalanib and platinum-based anticancer drugs in chemotherapy.1. Data
We have recently reported that vatalanib, an orally active small molecule multi-tyrosine kinase
inhibitor [1], can sensitize multidrug resistant (MDR) colon cancer cells to chemotherapy under
hypoxia by inhibiting two MDR transporters ABCB1 and ABCG2 [2].
The data available in this paper are: (a) apparent circumvention of oxaliplatin resistance in
HCT116/Oxa cells by combination of vatalanib and oxaliplatin (Table 1 and Fig. 1); (b) reduction of the
upregulated ATP7A expression in resistant HCT116/Oxa cells by vatalanib (Figs. 2 and 3); (c) inhibition
of ABCC2-mediated drug efﬂux in resistant HCT116/Oxa and ABCC2 stably-transfected HEK293/ABCC2
cells by vatalanib (Fig. 4); (d) increase in ABCC2 ATPase activity by vatalanib (Fig. 5); and (e) increase
in cellular Pt accumulation in resistant HCT116/oxa cells by vatalanib (Fig. 6).2. Experimental design, materials and methods
2.1. Materials
5(6)-Carboxy-20,70-dichloroﬂuorescein diacetate (CDCFDA) was purchased from Biotium Inc.
(Hayward, CA, USA). MK571 was obtained from Tocris Bioscience (Bristol, UK). Oxaliplatin was
Fig. 1. Vatalanib sensitized oxaliplatin-resistant HCT116 to oxaliplatin-induced apoptosis. (A) HCT116 parental cell line and its
oxaliplatin-resistant subline were exposed to oxaliplatin (10 μM), vatalanib (2 μM) alone, or their combination for 48 h before
harvest for apoptosis assay. A representative set of data from three independent experiments is shown. (B) Summary of
apoptosis assay data from three independent experiments. Data are presented in histogram as means7SD.
Table 1
Anticancer activity (IC50, μM) of oxaliplatin and its combination with vatalanib in a pair of parental and oxaliplatin-resistant
human colon cancer cell lines (HCT116 and HCT116/Oxa, respectively), and ABCC2 stably-transfected HEK293/ABCC2 and its
backbone vector transfected HEK293/pcDNA3 cell lines.
Cell line IC50 of oxaliplatin7SD (fold resistance)
Oxaliplatin Oxaliplatinþvatalanib
(1 μM)
Oxaliplatinþvatalanib
(2 μM)
HCT116
parental
1.4570.26 (1) 1.6170.21 (1.1) 1.3270.23 (0.9)
HCT116/
Oxa
69.677.3 (48) 23.576.9 (23)n 8.5170.65 (5.9)n
HEK293/
pcDNA3
0.5170.35 (1) 0.6370.29 (1.2) 0.5970.17 (1.2)
HEK293/
ABCC2
12.671.5 (25) 8.5271.15 (17)n 3.5570.86 (7.0)n
n po0.05, difference from oxalipatin alone in the resistant cells.
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from Selleckchem (Houston, TX, USA).
Fig. 2. mRNA expression of ABCC2 (A) and ATP7A (B) in parental HCT116 and oxaliplatin-resistant HCT116/Oxa cells treated
with or without vatalanib (1 or 2 μM, 24 h). Relative mRNA expression of the transporters are shown after normalization with
β-actin. The expression in the parental HCT116 cells was set as 10 for comparison. * po0.05, compared with untreated cells.
(C) Real-time RT-PCR analysis of the downregulation of ATP7B in HCT116/Oxa cells by vatalanib with or without a 4-h pre-
treatment of actinomycin D (5 μg/mL).
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The human embryonic kidney cell line HEK293 and its stable pcDNA3- and ABCC2-transfected
sublines were used to demonstrate the speciﬁc effect of vatalanib on ABCC2. The pcDNA3-transfected
HEK293 cells were kind gift obtained from Dr. Susan Bates (National Cancer Institute, NIH, Bethesda, MD,
USA). ABCC2 plasmid DNA for stable transfection was purchased from GeneCopeia (Rockville, MD, USA).
The transfected cells were cultured in complete DMEM medium supplemented with 2 mg/mL G418.
Oxaliplatin resistance was induced in the human colon cancer cell lines HCT116 (maintained in complete
RPMI1640 medium) by prolonged incubation in progressively increasing concentration of oxaliplatin.
Individual clones were obtained during the process and they were evaluated for sensitivity to oxaliplatin.
The most resistant clone was used in the study (IC50¼69.677.3 μM) (IC50 of oxaliplatin in parental
HCT116 cells was 1.4570.26 μM). Characterization of the HCT116/Oxa cells revealed an increase in
expression of the efﬂux transporters (ABCC2 and ATP7A) (Fig. 2), a reduction in drug accumulation
(Fig. 5), and elevated intracellular GSH content (Section 2), relative to the parental HCT116 cells.
Fig. 3. mRNA expression of other transporters implicated in Pt resistance: ABCC6 (A), ATP7B (B) and LRP (C) in parental HCT116
and oxaliplatin-resistant HCT116/Oxa cells treated with or without vatalanib (1 or 2 μM, 24 h). Relative mRNA expression of
these efﬂux transporters are shown after normalization with β-actin. The expression in the parental HCT116 cells was set as 10
for comparison. No statistical signiﬁcant difference was observed between the treatment groups.
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Fig. 4. Inhibition of ABCC2-mediated efﬂux of ﬂuorescent probe substrate CDCF by vatalanib in ABCC2-overexpressing HCT116/
Oxa cells (A) and ABCC2 stably-transfected HEK293/ABCC2 cells (B). Data obtained in the HCT116 parental cells and the
backbone vector transfected HEK293/pcDNA3 cells is also shown as control for comparison. Top panel: Representative efﬂux
histogram from three independent experiments are shown. Bottom panel: The relative ﬂuorescent probe retention was also
quantiﬁed by setting the value in transporter-overexpressing cells in the absence of vatalanib as 10.
Fig. 5. Effect of vatalanib on the ATPase activity of ABCC2. The vanadate-sensitive ATPase activity of ABCC2 in the recombinant
transporter proteins obtained from cell membrane fraction was determined at different concentrations of vatalanib. ATP
hydrolysis was monitored by measuring the amount of inorganic phosphate released using a colorimetric assay. In the presence
of vatalanib, all of the stimulated ABCC2 ATPase activity was signiﬁcantly different from the basal level (po0.05).
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The growth inhibitory effect of oxaliplatin and vatalanibwas evaluated by the sulforhodamine B assay as
described previously [3]. For the combination drug treatment, drugs were given simultaneously for 72 h.
2.4. Flow cytometric analysis of ABCC2 transporter activity
A ﬂow cytometry-based assay was employed to study the inhibition of ABCC2 transport activity by
vatalanib in an ABCC2 stable transfected HEK293 cells and an ABCC2-overexpressing oxaliplatin-resistant
Fig. 6. Cellular Pt accumulation in oxaliplatin (100 μM, 4 h)-incubated HCT116 and HCT116/Oxa cells in the presence of 1 or
2 μM vatalanib. In pilot experiments, drug accumulation was found to be increased in a linear manner with increasing drug
concentration up to at least 400 μM. Cell lysates obtained were subjected to concentrated HNO3 digestion before analysis by
Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES). The absorbance of Pt at 265.95 nm was used for quan-
tiﬁcation. Protein concentration of the cell lysate was measured separately by the Bradford method for normalization purpose.
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membrane-permeable probe 5(6)-carboxy-20,70-dichloroﬂuorescein diacetate (CDCFDA) was used. After
getting into the cells, CDCFDA is hydrolyzed to give the ﬂuorescent 5(6)-carboxy-20,70-dichloroﬂuorescein
(CDCF), which has been shown to be a speciﬁc substrate for ABCC2 [4]. The retention of the ﬂuorescent
CDCF in the cells is therefore used to indicate the efﬂux activity of ABCC2 in the cells. The cells were
incubated with 0.5 μM CDCFDA and vatalanib at various concentrations at 37 °C and 5% CO2 for 30 min.
Subsequently, the cells were washed with cold complete medium and then incubated for 1 h at 37 °C in
CDCFDA-free medium continuing with the same concentration of vatalanib to obtain the efﬂux histogram.
Inhibitors of the transporter ABCC2 is expected to shift the inhibitor/efﬂux histogram to the right, indi-
cating retention of the ﬂuorescent substrate in the cells. Inhibitors speciﬁc for ABCC2 (MK571 (25 μM))
were used as control for comparison. Samples were analyzed on an LSRFortessa Cell Analyzer (BD Bios-
ciences, San Jose, CA, USA). CDCF ﬂuorescence was detected with a 488-nm argon laser and a 530-nm
bandpass ﬁlter. At least 10,000 events were collected for all ﬂow cytometry studies. Cell debris was
eliminated by gating on forward versus side scatter and dead cells were excluded by propodium iodide
staining. All assays were performed in three independent experiments.
2.5. ABCC2 transporter ATPase assay
The effect of vatalanib on the vanadate-sensitive ATPase activity of ABCC2 in cell membrane
prepared from High-Five insect cells was measured by using the BD Gentest ATPase assay kit (BD
Biosciences) according to the manufacturer’s instructions.
2.6. Cellular Pt accumulation
Brieﬂy, ABCC2-stable transfected HEK293 cells and ABCC2-overexpressing human colon cancer
HCT116 cells were incubated with 100 μM oxaliplatin at 37 °C for 4 h. In pilot experiments, drug
accumulation was found to be increased in a linear manner with increasing drug concentration up to
at least 400 μM. Afterward, the cells were washed twice with ice-cold PBS and then harvested in
NETN buffer (100 mM NaCl, 20 mM Tris HCl (pH 8.0), 0.5 mM EDTA, 0.5% NP-40), sonicated, and
subjected to concentrated HNO3 digestion before analysis by Inductively Coupled Plasma Optical
Emission Spectroscopy (ICP-OES) (Perkin Elmer Optima 4300DV, UK). The absorbance of Pt at
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rately by the Bradford method for normalization purpose.
2.7. Reverse transcription and quantitative real-time PCR
Real-time quantitative reverse transcription PCR was performed as described previously [2] to
evaluate the expression of ABCC2, ABCC6, ATP7A, ATP7B and LRP in HCT116 and HCT116/Oxa cells
treated with or without vatalanib.
2.8. Annexin V apoptosis assay
HCT116 parental cell line and its oxaliplatin-resistant subline HCT116/Oxa were grown on a 60-mm
tissue culture dish at a density of about 2.0105 cells/well. They were treated for 48 h with 10 μM oxa-
liplatin in the presence or absence of 2 μMvatalanib. At the end of the treatment, both ﬂoating and attached
cells were collected and washed twice with ice-cold phosphate buffer solution. The extent of apoptosis was
determined by using the APC annexin V apoptosis kit (BD Bioscience, San Jose, CA, USA) according to the
manufacturer’s instructions. Cells positive for both annexin V and 7-AAD were considered apoptotic.
2.9. Determination of cellular GSH content
Cellular GSH content was determined in parental HCT116 and oxaliplatin-resistant HCT116/Oxa
cells by the GSH-Glo Glutathione assay kit (Promega, Madison, WI, USA). Protein concentration of the
cell lysate was measured separately by the Bradford method for normalization purpose.
2.10. Data analysis and statistics
All experiments were repeated at least three times. The statistical software SPSS16.0 (IBM, Armonk, NY,
USA) was used for data analysis. Statistical signiﬁcance was determined at po0.05 by the Student’s t-test.Acknowledgments
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